Skip to Main Content

Author Details

Andr?? S Bachmann
College of Human Medicine, Michigan State University
1998
64
22
Emma Lundberg (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37469105Bachmann-Bupp syndrome and treatment.Dev Med Child Neurol2024
36848144New K50R mutant mouse models reveal impaired hypusination of eif5a2 with alterations in cell metabolite landscape.Biol Open2023
37092498Two New Cases of Bachmann-Bupp Syndrome Identified through the International Center for Polyamine Disorders.Med Sci (Basel)2023
35208252Combined Plasma and Urinary Metabolomics Uncover Metabolic Perturbations Associated with Severe Respiratory Syncytial Viral Infection and Future Development of Asthma in Infant Patients.Metabolites2022
36223680Synthesis and evaluation of small molecule inhibitors of LSD1 for use against MYCN-expressing neuroblastoma.Eur J Med Chem2022
36188294Structure and Enzymatic Activity of an Intellectual Disability-Associated Ornithine Decarboxylase Variant, G84R.ACS Omega2022
35100927Pharmacological targeting of polyamine and hypusine biosynthesis reduces tumour activity of endometrial cancer.J Drug Target2022
34282722Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease.Elife2021
35497564Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation.RSC Adv2021
33851876Balancing precision versus cohort transcriptomic analysis of acute and recovery phase of viral bronchiolitis.Am J Physiol Lung Cell Mol Physiol2021
33806076Emerging Role of <i>ODC1</i> in Neurodevelopmental Disorders and Brain Development.Genes (Basel)2021
34796899Structural basis of binding and inhibition of ornithine decarboxylase by 1-amino-oxy-3-aminopropane.Biochem J2021
34477286Expanding the phenotype: Four new cases and hope for treatment in Bachmann-Bupp syndrome.Am J Med Genet A2021
34129075Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma.Cancer Chemother Pharmacol2021
32786875Allicin, a Potent New Ornithine Decarboxylase Inhibitor in Neuroblastoma Cells.J Nat Prod2020
31778912Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.Leuk Res2020
33248372Gene expression signatures identify paediatric patients with multiple organ dysfunction who require advanced life support in the intensive care unit.EBioMedicine2020
30639262Anti-tumor effect of sulfasalazine in neuroblastoma.Biochem Pharmacol2019
31249027Biochemical features of primary cells from a pediatric patient with a gain-of-function <i>ODC1</i> genetic mutation.Biochem J2019
29269255Immunoproteasome inhibition and bioactivity of thiasyrbactins.Bioorg Med Chem2018
30239107Novel de novo pathogenic variant in the ODC1 gene in a girl with developmental delay, alopecia, and dysmorphic features.Am J Med Genet A2018
30115881Polyamine Biosynthetic Pathway as a Drug Target for Osteosarcoma Therapy.Med Sci (Basel)2018
29977157Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.Cancer Cell Int2018
30404920Polyamine synthesis as a target of <i>MYC</i> oncogenes.J Biol Chem2018
30275178Thiasyrbactins Induce Cell Death <i>via</i> Proteasome Inhibition in Multiple Myeloma Cells.Anticancer Res2018
29295892Synergistic drug combination GC7/DFMO suppresses hypusine/spermidine-dependent eIF5A activation and induces apoptotic cell death in neuroblastoma.Biochem J2018
29240775Ornithine decarboxylase as a therapeutic target for endometrial cancer.PLoS One2017
26907687Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.J Biol Chem2016
26018967A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.PLoS One2015
26093909Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target.BMC Cancer2015
24096079Novel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation.J Mol Biol2014
25452693Withaferin A Inhibits STAT3 and Induces Tumor Cell Death in Neuroblastoma and Multiple Myeloma.Biochem Insights2014
25315710Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients.Cell Oncol (Dordr)2014
23457004AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.Int J Cancer2013
23440329PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.Int J Oncol2013
23440295DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma.Int J Oncol2013
22196580Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.Pharm Biol2012
22870914Activity enhancement of the synthetic syrbactin proteasome inhibitor hybrid and biological evaluation in tumor cells.Biochemistry2012
22213050PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.Int J Cancer2012
20830349The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity.Chem Commun (Camb)2011
19960435The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.Int J Cancer2010
20362557Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.Biochem Pharmacol2010
20412121Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: Influence on cell survival and migration.Cancer Sci2010
19359491Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition.Proc Natl Acad Sci U S A2009
19584241Inhibition of S-adenosylmethionine decarboxylase by inhibitor SAM486A connects polyamine metabolism with p53-Mdm2-Akt/protein kinase B regulation and apoptosis in neuroblastoma.Mol Cancer Ther2009
19746508Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines.Chembiochem2009
18395978Expression profile of PRAF2 in the human brain and enrichment in synaptic vesicles.Neurosci Lett2008
18853901Proteasome inhibitors in pediatric cancer treatment.Hawaii Med J2008
19047162Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in neuroblastoma.Cancer Res2008
18401409A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism.Nature2008
  • 1 - 50 of 64

Recommended Authors

Chelsea Mayoh
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2016
Number of shared co-authors 0
Pasqualino De Antonellis
University of Naples
Career Start Year 2010
Number of shared co-authors 0
Young K Song
National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Michelle J Henderson
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 2002
Number of shared co-authors 1
Daniel Martinez
Perelman School of Medicine at the University of Pennsylvania
Career Start Year 2002
Number of shared co-authors 1
Barak Rotblat
Ben-Gurion University of the Negev
Career Start Year 2002
Number of shared co-authors 0
Viktoria Marquardt
German Cancer Research Center (DKFZ)
Career Start Year 2001
Number of shared co-authors 0
Fan Yang
West China Second Hospital, Sichuan University
Career Start Year 2000
Number of shared co-authors 0
Yan Liu
Chengdu Medical College
Career Start Year 1999
Number of shared co-authors 0
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 0
Dalia Barsyte-Lovejoy
University of Toronto, College St
Career Start Year 1999
Number of shared co-authors 0
Mahadev Rao
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences
Career Start Year 1998
Number of shared co-authors 0
Qing-Rong Chen
Center for Biomedical Informatics and Information Technology
Career Start Year 1996
Number of shared co-authors 0
Jose Antonio Rodriguez
University of the Basque Country (UPV/EHU)
Career Start Year 1995
Number of shared co-authors 0
Kristina A Cole
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1994
Number of shared co-authors 0
Olaf Witt
Hopp Children's Cancer Center Heidelberg (KiTZ)
Career Start Year 1993
Number of shared co-authors 1
Xiao-Nan Li
Northwestern University
Career Start Year 1992
Number of shared co-authors 1
Ute Fischer
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 0
Alessandro Datti
University of Perugia
Career Start Year 1991
Number of shared co-authors 0
John Easton
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 0
Ricky W Johnstone
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 0
Antonio Iavarone
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
Career Start Year 1989
Number of shared co-authors 1
Glenn M Marshall
Children's Cancer Institute, Lowy Cancer Research Centre
Career Start Year 1989
Number of shared co-authors 1
John M Maris
Children's Hospital of Philadelphia
Career Start Year 1985
Number of shared co-authors 1
James M Olson
Clinical Research Division, Fred Hutchinson Cancer Center
Career Start Year 1985
Number of shared co-authors 1
Anna Lasorella
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
Career Start Year 1984
Number of shared co-authors 1
Charles Patrick Reynolds
Cancer Center, Texas Tech University Health Sciences Center
Career Start Year 1975
Number of shared co-authors 0
Michelle Haber
School of Clinical Medicine
Career Start Year 1973
Number of shared co-authors 1
Peter J Houghton
The University of Texas Health Science Center at San Antonio
Career Start Year 1971
Number of shared co-authors 0

Collaborators

Dirk Geerts
Amsterdam University Medical Center
Co-authored papers 17
Jan Koster
Amsterdam University Medical Centers location AMC
Co-authored papers 10
Dana-Lynn T Koomoa
University of Hawai'i at Hilo
Co-authored papers 8
Tamas Borsics
Cancer Research Center of Hawaii, University of Hawaii at Manoa
Co-authored papers 3
Chia-En A Chang
Co-authored papers 2
Kenneth Wester
Uppsala University
Co-authored papers 2
Ronghui Xu
University of California San Diego
Co-authored papers 1
Charles E Schwartz
Co-authored papers 1
Leonard S Sender
Co-authored papers 1
Christoph Driessen
Cantonal Hospital St. Gallen
Co-authored papers 1
George L Maxwell
Women's Health Integrated Research Center, Inova Health System
Co-authored papers 1
Emma Lundberg (CM4AI)
Stanford University
Co-authored papers 1
Release 1.2